Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus IBU TAB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus IBU TAB 200.
ALEVE vs IBU-TAB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)